Non-Hodgkin Lymphoma (NHL)

Latest News
June 19th 2025

Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

June 17th 2025

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

June 7th 2025

Biomarker-Adapted Treatment Effective in High-Risk LBCL

Video Interviews
View All
May 20th 2025

MRD Status Guides Consolidation With Cema-Cel in ALPHA3 Trial: Fred Locke, MD

May 14th 2025

Future Research Priorities for Non-Hodgkin Lymphomas: Craig A. Portell, MD

April 21st 2025

Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD

April 11th 2025

Newly Approved Triplet Regimen Boosts Survival in R/R LBCL: Craig Portell, MD

April 7th 2025

Limited Clinical Insight Poses Barrier to Optimal NHL Treatment: Andrew Evens, DO

April 5th 2025

Unique Challenges for Younger NHL Populations: Andrew Evens, DO

March 17th 2025

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

March 7th 2025

Overcoming Delays in CAR T for Large B-Cell Lymphoma

February 24th 2025

Allogeneic vs Autologous CAR T-Cell Therapy Explained

July 13th 2024

Dr Anna Sureda on the Evolving Treatment Landscape for Relapsed/Refractory DLBCL, Follicular Lymphoma

Podcasts
View All
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Continuing Medical Education
View All
June 21st 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 21st 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
June 21st 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
June 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
June 21st 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas. | Image credit: kalpis - stock.adobe.com
May 28th 2025

CD20 Levels May Impact BsAb Response in B-Cell Lymphomas

Jared Kaltwasser
The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.
The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser
Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.
Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor
A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Q&A with Andrew Evens, DO
May 12th 2025

Collaboration Advances Lymphoma Care: Andrew Evens, DO

Kyle Munz Andrew Evens, DO
Multidisciplinary efforts help promote the success of clinical trials and innovation for patients with various forms of lymphoma, explained Andrew Evens, DO.
Andrew Evens, DO
May 2nd 2025

Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

Kyle Munz Andrew Evens, DO
To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com
April 16th 2025

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

Maggie L. Shaw
A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw
In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
ASH logo | images: ASH
March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

Mary Caffrey
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
CAR T | Image Credit: © Funny-stock.adobe.com
March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Maggie L. Shaw
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Patients with R/R transformed DLBCL have modest 4-year event free and overall survival rates under 50%, making disease management a persistent challenge | SuriyaPhoto - stock.adobe.com
March 14th 2025

Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment

Kyle Munz
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) could be a well-tolerated and effective treatment option in non-Hodgkin lymphoma.
BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com
February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Bispecific antibody | Image credit: MD Anderson
February 19th 2025

Banner Year for Bispecifics as Therapies Advance Into the Community Setting

Ryan Flinn
A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com
February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

Kyle Munz
A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Maggie L. Shaw
Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).
Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg
February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Maggie L. Shaw
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.
Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com
January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava
The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com
January 29th 2025

Study Expands Knowledge of Prognostic Markers in Extranodal NHL

Kyle Munz
Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.
There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com
January 27th 2025

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

Kyle Munz
Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
January 17th 2025

FDA Grants 2 Traditional Approvals for Acalabrutinib

Maggie L. Shaw
The Bruton tyrosine kinase inhibitor was approved in combination with bendamustine and rituximab in previously untreated mantle cell lymphoma (MCL) ineligible for autologous hematopoietic stem cell transplantation and as monotherapy in previously treated MCL.
Genetic analysis-angellodeco-stock.adobe.com
December 18th 2024

The Role of Geriatric Assessment Tools in Enhancing Oncology Care: ASH 2024

Giuliana Grossi
A pair of studies from The American Society of Hematology (ASH) Annual Meeting & Exposition provides insights into the prognostic utility of geriatric assessment tools and their role in tailoring therapy to improve patient outcomes.
Senior elderly older man smiling with nurse - Beaunitta Van Wyk:peopleimages.com - stock.adobe.com
December 17th 2024

Fixed-Duration Epcoritamab Is Active, Safe in Older Patients With Newly Diagnosed LBCL

Russ Conroy
Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.
non-Hodgkin lymphoma | Image Credit: © jarun011-stock.adobe.com
December 9th 2024

Epcoritamab Offers Durable Results in Relapsed B-Cell Lymphoma

Maggie L. Shaw
This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on epcoritamab, currently being investigated in the Epcore NHL-1 trial.
Non-Hodgkin Lymphoma | Image credit: Saiful52 - stock.adobe.com
October 30th 2024

Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies

Gayle Turim Dickstein
A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.
Thomas Jefferson | Image: Thomas Jefferson University
October 13th 2024

Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy

Ryan Flinn
Microbiologist conducts research in laboratory | Image Credit: © Seventyfour - stock.adobe.com
October 8th 2024

Preclinical Model Suggests Efficacy of Combining Capivasertib With Venetoclax Against DLBCL

Karen Jacobson-Sive
Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).
Lymphoma word block image | Image Credit: © airdone- stock.adobe.com
September 25th 2024

Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL

Nameera Temkar, MD
A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.
NHL cells | image credit: sovova - stock.adobe.com
September 21st 2024

Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL

Kimberly Rath, PharmD
A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL).
Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com
September 13th 2024

Patients With B-Cell Cancers Have History of Increased Antimicrobial Use

Nameera Temkar, MD
Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.
Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com
September 5th 2024

Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma 

Karen Jacobson-Sive
Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).
Dr Jason Romancik, Emory Winship Cancer Institute
August 30th 2024

Dr Jason Romancik on Novel Lymphoma Therapies, Increasing Costs of Care

Rose McNulty
Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.
12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo